Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R, Gao GX, Chen JP, Wang JS, Wang XM, Zeng Y, Bai QX, Zhang T, Yang L, Dong BX, Gu HT, Shu MM, Hao CX, Wang JH, Zhang N, Chen XQ. Liang R, et al. Among authors: zhang n, zhang t. Hematol Oncol. 2017 Dec;35(4):619-629. doi: 10.1002/hon.2325. Epub 2016 Oct 10. Hematol Oncol. 2017. PMID: 27723108 Free PMC article. Clinical Trial.
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y, Shen H, Xu L, Feng J, Tang H, Zhang N, Chen X, Gao G. Zheng Y, et al. Among authors: zhang n. J Immunol Res. 2018 Jun 27;2018:7646913. doi: 10.1155/2018/7646913. eCollection 2018. J Immunol Res. 2018. PMID: 30050957 Free PMC article. Review.
Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X, Jia S, Chu Y, Tian B, Gao Y, Zhang C, Zheng Y, Jia W, Liu X, Yuan R, Zhang N, Feng J, Dong H, Xin X, Chang Z, Cao Z, Tang H, Gao G. Liu X, et al. Among authors: zhang n, zhang c. Front Oncol. 2022 Sep 14;12:938550. doi: 10.3389/fonc.2022.938550. eCollection 2022. Front Oncol. 2022. PMID: 36185185 Free PMC article.
A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.
Wu Z, Wang C, Lyu Y, Lin Z, Lu M, Wang S, Wang B, Yang N, Li Y, Wang J, Duan X, Zhang N, Gao J, Zhang Y, Hao M, Wang Z, Gao G, Liang R. Wu Z, et al. Among authors: zhang n, zhang y. Front Oncol. 2023 Mar 28;13:1104425. doi: 10.3389/fonc.2023.1104425. eCollection 2023. Front Oncol. 2023. PMID: 37056341 Free PMC article.
17,677 results
You have reached the last available page of results. Please see the User Guide for more information.